Actively Recruiting

Phase Not Applicable
Age: 18Years - 100Years
FEMALE
ID02993900

A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite

Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2025-12-18

54

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

Sponsors

S

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the use of magnetic resonance imaging (MRI) to guide brachytherapy treatment in gynecologic cancers such as cervical, uterine, vaginal, vulvar, and bladder cancers. This study aims to determine if MRI can more accurately assess tumors during brachytherapy compared to the commonly used CT scans, potentially improving treatment precision and reducing radiation exposure to healthy tissues. The goal is to improve how doctors plan radiation doses and reduce treatment-related side effects. The study involves using MRI-guided brachytherapy, where MRI scans help precisely place the radiation applicator to target the tumor. Investigators will compare radiation doses to organs at risk during MRI-based planning versus standard CT-based planning. The study will assess radiation dose thresholds that may cause toxicity and compare toxicity rates at 6 months, 1 year, and 2 years after treatment to improve future dose recommendations. Participants will undergo MRI scans to guide their brachytherapy treatment and will be monitored for treatment-related side effects and tumor control over time. Researchers will measure changes in radiation dosing over 3 years and track toxicity rates, local tumor failure, and survival at various intervals up to 2 years. The total participation duration includes treatment and follow-up monitoring to evaluate the safety and effectiveness of MRI-guided brachytherapy.

CONDITIONS

Brief Title

Image-Guided Gynecologic Brachytherapy

Who Can Participate

Age: 18Years - 100Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants must have confirmed carcinoma by tissue or cell examination.
  • Eligible cancer types include cervical (Stage I-IVA or vaginal recurrence), uterine (Stage IIIB with vaginal involvement, inoperable, or vaginal recurrence), vaginal (Stage I-IVA or vaginal recurrence), vulvar (Stage I-IVA or recurrence), or urethra carcinoma as decided by the doctor.
  • Patients who have had prior radiation or chemotherapy may join.
  • Age must be over 18 years.
  • Life expectancy must be greater than 6 months.
  • ECOG performance status must be less than 2 or as determined by the doctor.
  • Must have had an MRI of the pelvis or PET-CT within 4 months before joining.
  • Must be able to understand and willing to sign informed consent.
Not Eligible

You will not qualify if you...

  • Having uncontrolled illness such as active infection, heart failure, unstable angina, irregular heartbeat, or psychiatric issues that prevent following study rules.
  • Absolute neutrophil count below 500 at enrollment.
  • History of metal in the head or eyes.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Duration of treatment procedure

Participants undergo image-guided brachytherapy where brachytherapy is precisely inserted with the assistance of magnetic resonance (MRI) scans.

1 treatment visit (in-person)

Follow-up

Duration - Up to 2 years

Participants are monitored for treatment-related toxicity, local failure, and survival over time after the brachytherapy treatment.

Visits at 3 months, 6 months, 1 year, and 2 years post-treatment

Trial Site Locations

Total: 1 location

1

The SKCCC at Johns Hopkins

Baltimore, Maryland, United States, 21287

Actively Recruiting

Loading map...

Research Team

S

Shirley DiPasquale, R.N.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Phase 1/2a Study of the Safety, Tolerability, and Prelimin...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here